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Abstract
Background: The Synapsins (SYN1, SYN2, and SYN3) are important players in the adult brain, given their
involvement in synaptic transmission and plasticity, as well as in the developing brain through roles in axon
outgrowth and synaptogenesis. We and others previously reported gene expression dysregulation, both as
increases and decreases, of Synapsins in mood disorders, but little is known about the regulatory mechanisms
leading to these differences. Thus, we proposed to study DNA methylation at theses genes’ promoter regions,
under the assumption that altered epigenetic marks at key regulatory sites would be the cause of gene expression
changes and thus part of the mood disorder etiology.
Methods: We performed CpG methylation mapping focusing on the three genes’ predicted CpG islands using the
Sequenom EpiTYPER platform. DNA extracted from post-mortem brain tissue (BA10) from individuals who had lived
with bipolar disorder (BD), major depressive disorder (MDD), as well as psychiatrically healthy individuals was used.
Differences in methylation across all CpGs within a CpG island and between the three diagnostic groups were
assessed by 2-way mixed model analyses of variance.
Results: We found no significant results for SYN1 or SYN3, but there was a significant group difference in SYN2
methylation, as well as an overall pattern of hypomethylation across the CpG island. Furthermore, we found a
significant inverse correlation of DNA methylation with SYN2a mRNA expression.
Conclusions: These findings contribute to previous work showing dysregulation of Synapsins, particularly SYN2, in
mood disorders and improve our understanding of the regulatory mechanisms that precipitate these changes likely
leading to the BD or MDD phenotype.
Keywords: Bipolar disorder, Major depressive disorder, DNA Methylation, Epigenetics, Mood disorders
Background
Synapsin genes – Synapsin I (SYN1), Synapsin II (SYN2),
and Synapsin III (SYN3) – are interesting candidates for
the etiology of mood disorders due to their involvement
in the adult brain in synaptic transmission and plasticity,
as well as in brain development in axon outgrowth and
synaptogenesis [1]. Genetic association studies have
linked SYN2 to epilepsy and schizophrenia, while brain
expression studies have shown significant dysregulation
in alcoholism, Huntington’s disease, schizophrenia and
bipolar disorder [2]. A nonsense mutation in the SYN1
gene was shown to cause familial epilepsy; and some
studies have suggested an association of SYN3 with
schizophrenia [Reviewed in: [1, 2]].
Though the literature provides ample evidence for
genetic associations and gene expression increases of
Synapsins in mood disorders, little has been done to
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elucidate the regulatory mechanisms that lead to these
disturbances. To date there is no evidence of altered
DNA methylation of these genes in mood disorders; only
one study of a single schizophrenia patient suggests
potentially variably methylated sites in the distal SYN3
promoter [3] and a recent study in rats proposes that
early life stress, a precipitant of depressive behavior, leads
to SYN1 transcription start site hypermethylation and re-
lated mRNA downregulation in the amygdala [4].
Since we previously reported Synapsins mRNA up-
regulation in mood disorders [5], we aimed to elucidate
the regulatory mechanisms that may explain this by
conducting a study of DNA methylation in putatively
regulatory regions of the genes. DNA methylation at
CpG islands has been most commonly associated to
expression regulation – thus we chose to focus on in
silico predicted islands at the proximal promoters of
SYN1 (845 bp) and SYN2 (975 bp), as well as at a distal
promoter of SYN3 (613 bp) [2].
Methods
Post-mortem prefrontal cortex (PFC) brain tissue from
Brodmann Area 10 used in this study was obtained from
the Douglas Bell-Canada Brain Bank (www.douglasbrain
bank.ca) as described elsewhere [5, 6]. All procedures in
this study were approved by the ethics review board of the
Douglas Mental Health University Institute and informed
consent for deposition in the brain bank and any resulting
research was obtained from the next of kin. Clinical infor-
mation, toxicology and history of psychoactive prescrip-
tion drugs were collected for both cases and controls.
Cases in this study were White Caucasian individuals with
diagnoses of BD type I or type II (n = 13) or MDD (n = 18)
and who died primarily by suicide. Controls were White
Caucasian individuals with neither current nor past psy-
chiatric diagnoses who died suddenly and could not have
undergone resuscitation or other medical intervention
(n = 14). We found no significant group differences in
gender, age, brain pH or refrigeration delay (Additional
file 1: Table S1).
We performed CpG methylation mapping focusing on
the three Synapsins’ predicted CpG islands, which over-
lapped part of the promoter regions as well as the first
exon and intron (Fig. 1a), using the EpiTYPER platform
(Sequenom, San Diego, CA), as described previously [7].
Briefly, genomic DNA was extracted using the QIAamp
DNA Mini Kit (QIAGEN, Toronto, CA) and concentra-
tions and 260/280 ratios were determined using the
Nanodrop 1000 spectrophotometer (Thermo Scientific).
Genomic DNA from each sample was bisulfite-treated
using the Epitect Bisulfite Kit (QIAGEN, Toronto, CA)
following the manufacturer’s guidelines. Due to the mass
threshold necessary for accurate measurement some
CpGs (typically close together) were clustered and thus
quantified together by the EpiTYPER software. Percent
methylation levels were reported for each cluster or indi-
vidual CpG.
Differences in methylation across all CpGs within a
CpG island and between the three diagnostic groups
were assessed by 2-way mixed model analyses of vari-
ance (ANOVA) with groups as the fixed factor and CpG
dinucleotides percent methylation level as the repeated
measure, followed by Fisher Least Significant Difference
(LSD) post-hoc analyses. Since there was no difference
between groups in regards to potential confounders: sex,
brain pH, post-mortem delay, or age (Additional file 1:
Table S1), no covariates were included in the mixed
model. Because the EpiTYPER system is able to detect
the methylation level in a mixture only as low as 5 %, we
excluded all CpGs where methylation levels were below
this threshold. Correlations between individual CpG per-
cent methylation values were reported using Pearson’s
correlation coefficients. In all cases, p-values were con-
sidered statistically significant at p ≤ 0.05 (labeled *) and
suggestive at p ≤ 0.1 (labeled #).
Results and discussion
In this study we explored the role of DNA methylation
at promoter-region CpG islands mapping to the three
synapsin genes: SYN1, SYN2, and SYN3. Given previous
evidence of gene expression changes in the prefrontal
cortex (PFC) we hypothesized that altered epigenetic
marks at key regulatory sites would be in part respon-
sible for this gene expression increase and thus part of
the mood disorder etiology. We chose to work with the
Brodmann Area 10 (BA10) given our previous findings
regarding synapsin gene expression in this region, and
more importantly its role in mood regulation shown
through imaging studies as well as documented deficits
in PFC-mediated working memory and executive func-
tion in BD [5, 8, 9]. The brain samples were obtained
from the Douglas-Bell Canada Suicide brain bank, and
as such the large majority of cases died by suicide while
the controls died by sudden natural causes. A limitation
of our study, and likely the larger part of postmortem
mood disorder research, is that we cannot distinguish ef-
fects of the suicidal status from effects of the mood dis-
order itself. For this reason we made sure to include two
diagnostic groups, and sought to identify differences be-
tween them that were unlikely to be a result of suicide.
We found no significant group differences for SYN1
(p = 0.718) or SYN3 (p = 0.449) (Additional file 2: Table
S2), but there was a significant group effect for SYN2 (p =
0.019, F = 4.127) (Additional file 2: Table S2; Fig. 1b inset).
Given the positive result, we performed LSD post-hoc
analyses for each CpG data point within the SYN2 CpG
island and found an overall pattern of hypomethylation
across the island, with a few CpGs remaining completely
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unaltered (Fig. 1b). We found significant hypomethylation
compared to controls in MDD at five loci and in BD
at one locus (Fig. 1b, Additional file 3: Table S3). Due
to the small differences between groups, no CpG
passed corrections for multiple testing at a nominal
p-value but all maintained suggestive significance
(Bonferroni, p-value ≤ 0.1). The most interesting locus
was at chr3:12046417-12046478, where three consecu-
tive CpGs were significantly hypomethylated in MDD
and their methylation levels strongly correlated across
individuals (Fig. 1b, Pearson’s correlation matrix). In
order to test whether there was a combined effect of
the three CpG sites identified at this locus in MDD,
we computed average CpG methylation values across
the three sites and found a significant 25 % decrease
in average methylation between MDD and control in-
dividuals at this locus (Additional file 4: Figure S1
Student’s T-Test, p-value = 0.03). This locus is part of
a binding site for EZH2 (Enhancer of Zeste homolog
2, or Enx1), a catalyst of mono- di- or tri-methylation
of histone H3 at lysine 27 [10]. Thus the DNA hypo-
methylation we observed at this locus could interfere
with recruitment of this factor and lead to altered
H3K27 methylation levels. Unfortunately, our previous
Fig. 1 DNA methylation is decreased in individuals with mood disorders at the SYN2 CpG island. a Graphical representations of the CpG islands
predicted at the promoter and first exons of Synapsin genes. b Percent methylation levels for individual CpGs at SYN2 show some significant
(p < 0.05) or suggestive (p < 0.1) decreased levels of DNA methylation in BD and more in MDD, while several CpGs have no differences at all. The
CpG-to-CpG correlation matrix shows some clusters of correlated percent methylation levels with others seemingly completely independent. The
cluster at chr3:12046417-12046478, where 3 consecutive CpGs have decreased DNA methylation levels, overlaps with a predicted binding site
for EZH2
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histone modification inquiries were limited to H3K4me3
[5] as is described in more detail later, but this finding sug-
gests that it would be interesting to assess other histone
modifications and their relationship to SYN2 gene expres-
sion. Furthermore, EZH2 has been shown to also serve as
a recruitment platform for DNA methyltransferases within
the context of the Polycomb repressive complexes 2 and
3, and its decreased binding would lead to reduced DNA
methylation [11]. This suggests that the hypomethyation
observed could also be a result of EZH2 binding.
Previous work from our group showed significant
mRNA up-regulation of the SYN2a isoform in BD and
the SYN2b isoform in MDD [5]. Furthermore, the CpG
island at SYN2, which is shared by both isoforms, was
preceded by a region of significantly enriched H3K4me3
in MDD [5]. Since the same brain samples were used for
the current study, we questioned whether our DNA
methylation findings correlated with mRNA expression
levels in these individuals. We computed the average
methylation level for each individual and performed a
Pearson’s correlation between these values and SYN2a
and SYN2b mRNA expression as well as H3K4me3 en-
richment and found a significant inverse correlation with
SYN2a mRNA expression (r = -0.318, p-value = 0.014)
and a suggestive inverse correlation with SYN2b mRNA
expression (r = -0.264, p-value = 0.069). This is the
expected direction, as promoter and first exon hypome-
thylation have been associated with increased gene
expression [12]. There was no significant correlation
with H3K4me3 enrichment, which is unexpected since a
strong negative correlation was reported between DNA
methylation and H3K4me3 at promoters and CpG
islands [13]. On the other hand it is not necessarily
surprising because the significant regions were not over-
lapping and it has been suggested that the correlation
between DNA methylation and histone modifications
may be genomic-region specific [14].
To our knowledge, this is the first study to show
evidence of altered DNA methylation at any of the
Synapsin genes in mood disorders; only one recent study
in rats proposed that early life stress, a precipitant of
depressive behavior, leads to SYN1 transcription start site
hypermethylation and related mRNA downregulation in
the amygdala [4]. It would be of great interest to see other
groups with access to similar post-mortem brain cohorts
explore DNA methylation at the Synapsin loci. Further-
more, it would be interesting to see this work replicated in
an analysis of single-cell or single-cell-type methylation
since likely the fairly small effect sizes we identified here
were in part due to cell-type heterogeneity within the tis-
sue used for DNA extraction. This is a typical limitation
of post-mortem brain epigenetic analysis, but incremental
steps are currently being taken toward developing reliable
methods for single-cell exploration [15–17].
Overall our current findings contribute to previous work
showing dysregulation of SYN2 in mood and other psychi-
atric disorders [18] and improve our understanding of the
regulatory mechanisms that may explain differential ex-
pression of this gene. Although these results are of inter-
est, regulatory mechanisms implicated in mood disorders
are complex and dysregulation at multiple levels likely
contributes to these complex phenotypes.
Conclusions
In this work we showed evidence of decreased promoter
DNA methylation which correlated with increased expres-
sion of Synapsin genes in mood disorders. This finding is
important as it contributes to our understanding of the
intricacies of mood disorder dysregulation at the genetic
and epigenetic level in the brain.
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